Medicinal chemistry of target family-directed masterkeys

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

2001 • 16,438 citations

The druggable genome

2002 • 3,099 citations

Drug Discovery: A Historical Perspective

2000 • 2,654 citations

The Properties of Known Drugs. 1. Molecular Frameworks

1996 • 2,042 citations

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists

1988 • 1,412 citations

A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening

2002 • 1,039 citations

New Goals for the U.S. Human Genome Project: 1998-2003

1998 • 848 citations

The Design of Leadlike Combinatorial Libraries

1999 • 765 citations

RECAPRetrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry

1998 • 646 citations

Privileged Molecules for Protein Binding Identified from NMR-Based Screening

2000 • 333 citations

Chapter 26. Privileged structures — An update

2000 • 299 citations

Properties of Known Drugs. 2. Side Chains

1999 • 271 citations

Comprehensive Survey of Combinatorial Library Synthesis: 2000

2001 • 259 citations

Development of a Virtual Screening Method for Identification of “Frequent Hitters” in Compound Libraries

2001 • 252 citations

Comprehensive Survey of Combinatorial Library Synthesis: 2005

2006 • 249 citations

Genomic sciences and the medicine of tomorrow

1996 • 240 citations

Kinase Inhibitors: Not Just for Kinases Anymore

2003 • 229 citations

An opioid benzodiazepine

1982 • 201 citations

Drug Development: The role of innovation in drug development

1997 • 172 citations

Strategic trends in the drug industry

2003 • 162 citations

Medicinal Chemistry: Challenges and Opportunities

2001 • 126 citations

In Quest of Tomorrow’s Medicines

1999 • 105 citations

Innovation Deficit in the Pharmaceutical Industry

1996 • 83 citations

Design and Synthesis of Pyrrolidine-5,5-trans-lactams (5-Oxohexahydropyrrolo[3,2-b]pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 2. Potency and Chirality

2001 • 68 citations

Trends in development cycles

2002 • 62 citations

Discovery of Further Pyrrolidine trans-Lactams as Inhibitors of Human Neutrophil Elastase (HNE) with Potential as Development Candidates and the Crystal Structure of HNE Complexed with an Inhibitor (GW475151)

2002 • 53 citations

Drug discovery today – and tomorrow

2000 • 46 citations

The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase—GW311616A a development candidate

2001 • 45 citations

Isolation of Translactone-containing Triterpenes with Thrombin Inhibitory Activities from the Leaves of Lantana camara

1998 • 45 citations

Design and Synthesis of Pyrrolidine-5,5-trans-lactams (5-Oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 1. The α-Methyl-trans-lactam Template

2000 • 44 citations

Combinatorial synthesis of 3-(Amidoalkyl) and 3-(Aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors

2002 • 43 citations

Novel Natural Product 5,5-trans-Lactone Inhibitors of Human α-Thrombin: Mechanism of Action and Structural Studies

1998 • 41 citations

Tifluadom, a κ-opiate agonist, acts as a peripheral cholecystokinin receptor antagonist

1986 • 27 citations

Pyrrolidine-5,5-trans-lactams. 1. Synthesis and Incorporation into Inhibitors of Hepatitis C Virus NS3/4A Protease

2002 • 26 citations

Thrombin inhibitors based on [5,5] trans-fused indane lactams

1999 • 21 citations

5,5-Trans lactone-containing inhibitors of serine proteases: Identification of a novel, acylating thrombin inhibitor

1998 • 17 citations

As biotech turns 20...

2002 • 17 citations

Pyrrolidine-5,5-trans-lactams. 2. The Use of X-ray Crystal Structure Data in the Optimization of P3 and P4 Substituents

2002 • 13 citations

Too many targets, not enough target validation

2001 • 13 citations

MAJOR DRUG FIRMS EKE OUT INCREASES

2003 • 1 citations